EGFR and head and neck squamous cell carcinoma: Meanwhile, following the EXTREME trial for R/M HNSCC, regimens containing cetuximab (Cmab)—an epidermal growth factor receptor (EGFR) inhibitor—are now a standard treatment for HNSCC (3).